Although researchers have identified various proliferation-associated biomarkers as prognostic indicators for glioma patients5–7, such as Par6, chromobox protein homolog 3 (CBX3) and nucleolar and spindle-associated protein 1 (NUSAP1), none of them has been routinely applied in clinical practice. The gene discussed is NUSAP1; the disease is central nervous system cancer.